Das UroLift^® System in der Behandlung des benignen Prostata-Syndroms (BPS)

Zusammenfassung

Minimalinvasive Therapieverfahren des benignen Prostatasyndroms (BPS) gewinnen bei ähnlich effektiver Therapiewirkung wie bewährte OP-Verfahren jedoch günstigerem Sicherheitsprofil zunehmend an Bedeutung. Unter den minimalinvasiven Verfahren hat sich in der klinischen Evaluation das UroLift-Verfahren in der langfristigen Beurteilung hinsichtlich postoperativer Ergebnisse sowie Komplikationsraten bewährt. Deutlich überlegen zeigt sich UroLift für den kompletten Erhalt der sexuellen Funktion, inklusive einer antegraden Ejakulation.

Abstract

Minimally-invasive treatment options for patients with LUTS due to benign prostatic obstruction (BPO) become more and more important because they provide equal long-term efficacy compared with the reference method TURP, while having a more favourable safety profile. There are promising results for PUL (Prostatic Urethral Lift – UroLift) with low complication rates. UroLift is clearly superior regarding the preservation of sexual functions without impairment of ejaculatory function.

Schlüsselwörter

benignes Prostatasyndrom - benigne Prostatahyperplasie - minimal invasive Therapie

Keywords

benign prostatic hyperplasia - minimally-invasive treatment - benign prostatic syndrome

• Literatur

• 1 Berges R. et al. Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU). Urologe A 2009; 48: 1503-1516
• 2 Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 2006; 7: 272-281
• 3 Berges R. et al. Management of the BPH syndrome in Germany: who is treated and how?. Eur Urol 1999; 36: 21-27
• 4 Höfner K, Dreikorn K, Berges R. et al. Leitlinie Therapie des Benignen Prostatasyndroms (BPS). 2014; S2e
• 5 Roehrborn CG, McVary KT. et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research, Inc.; 2010
• 6 Lu-Yao GL. et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 1994; 44: 692-698 discussion 698-699.
• 7 Magistro G. et al. Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms. Eur Urol 2017; 72: 986-997
• 8 Magistro G, Stief CG, Gratzke C. New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol 2015; 12: 461-471
• 9 Walsh LP. State of the art: Advanced techniques for prostatic urethral lift for the relief of prostate obstruction under local anesthesia. Can J Urol 2017; 24: 8859-8864
• 10 Shah BB. et al. Prostatic Urethral Lift: Does Size Matter?. J Endourol 2018; 32: 635-638
• 11 McAdams S. et al. Holmium Laser Enucleation of the Prostate After Prostatic Urethral Lift Surgery: Feasibility and Technical Considerations from a Multi-Institutional Case Series. J Endourol 2017; 31: 774-779
• 12 Gravas S, Bach T, Bachmann A. et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Urology; 2016
• 13 Roehrborn CG. et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol 2013; 190: 2161-2167
• 14 Roehrborn CG. et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24: 8802-8813
• 15 Gratzke C. et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 2017; 119: 767-775